To understand how mutations cause conditions like CDKL5 it is worthwhile understanding the basics of how genes work. Genes are contained within our DNA. A gene is the “blueprint” for making a protein and is composed of a chain of bases orbase-pairs. There are 4 bases used in DNA, Adenine, Cytosine, Guanine and Thymine. They are often referred to as base-pairs because in DNA they exist in pairs, Adenine always pairs with Thymine, and Guanine with Cytosine. This was one of the key findings that led to the discovery of the structure of DNA by Crick and Watson in 1953.
Genetics of CDKL5
How genes work
Cell to DNA

DNA to Protein

A gene is a specific section of DNA that codes for a protein. A protein consists of a chain of amino acids, and every 3 base-pairs, called a codon, in the gene code for an amino acid.
The code is converted into a protein via RNA. If the gene is the “blueprint” then RNA is the “template” that is taken from the gene and used to make the protein.
So, the RNA template is taken from DNA, through a process called transcription. A structure called a ribosome (a sort of protein factory) then reads the RNA template and uses it to construct a chain of amino acids through a process called translation – and hey presto, you have a protein!
Just as a sentence is made up of words and spaces between the words, so a gene is made up of exons (the words) and introns (the spaces between). When the genetic code is being read and converted into a protein, the introns are removed and the exons then spliced together to produce the genetic code that will ultimately be read to make the protein.
What is interesting, however, is that the spaces between the words (introns) are actually much longer that the words (exons) themselves.
So a gene might look like this.
Furthermore, it may be that the introns actually contain important information about how the gene, or indeed another gene further along the DNA chain, is read and converted into a protein.

The CDKL5 Gene
And so, a relationship between mutation and the severity of the CDKL5-disorder remains unclear.
Interestingly, a review from France published in 2011, included a summary of the clinical details of 77 previously published cases of CDKL5. Of these, the best motor skills of 51 individuals are listed, of whom 21 appear to have various walking abilities.
Looking at walking ability in relation to the site of mutation, according to which exon is affected, a trend emerges.
Analysis of the data shows that only 30% of individuals with a mutation affecting exons 1 to 11 have some sort of walking ability whereas, that figure increases to 61% in those who have a mutation affecting exons 12 to 21.
This is obviously a relatively crude analysis and doesn’t take into account other factors such as the type of mutation, the degree of X-inactivation and multi-exon or intron involvement.
Other clinical factors may also be relevant such as the amount of therapy each individual has had or whether there are other orthopaedic issues such as hip or spine problems.
Also, some relatively younger children may go on to develop an ability to walk whilst others who were walkers may lose their ability, perhaps because of poor epilepsy control. Furthermore, the numbers involved in this study are relatively small.
Therefore, to help get answers to these questions a new CDKL5 Disorder International Registry Database has recently been developed. As more information about children with a CDKL5-disorder is recorded then the answers to many of these questions will hopefully become available.
Reproduced by the kind permission of Dr Martyn Newey, our Medical Trustee. www.supporting-cdkl5.co.uk






